JP2016509062A5 - - Google Patents

Download PDF

Info

Publication number
JP2016509062A5
JP2016509062A5 JP2015558996A JP2015558996A JP2016509062A5 JP 2016509062 A5 JP2016509062 A5 JP 2016509062A5 JP 2015558996 A JP2015558996 A JP 2015558996A JP 2015558996 A JP2015558996 A JP 2015558996A JP 2016509062 A5 JP2016509062 A5 JP 2016509062A5
Authority
JP
Japan
Prior art keywords
alkyl
group
substituted
cycloalkyl
coor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015558996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509062A (ja
JP6186012B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/017688 external-priority patent/WO2014130810A1/en
Publication of JP2016509062A publication Critical patent/JP2016509062A/ja
Publication of JP2016509062A5 publication Critical patent/JP2016509062A5/ja
Application granted granted Critical
Publication of JP6186012B2 publication Critical patent/JP6186012B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015558996A 2013-02-25 2014-02-21 C−3アルキルおよびアルケニル修飾ベツリン酸誘導体 Expired - Fee Related JP6186012B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361768630P 2013-02-25 2013-02-25
US61/768,630 2013-02-25
PCT/US2014/017688 WO2014130810A1 (en) 2013-02-25 2014-02-21 C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv

Publications (3)

Publication Number Publication Date
JP2016509062A JP2016509062A (ja) 2016-03-24
JP2016509062A5 true JP2016509062A5 (enExample) 2016-12-15
JP6186012B2 JP6186012B2 (ja) 2017-08-23

Family

ID=50288267

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015558996A Expired - Fee Related JP6186012B2 (ja) 2013-02-25 2014-02-21 C−3アルキルおよびアルケニル修飾ベツリン酸誘導体

Country Status (15)

Country Link
US (1) US9249180B2 (enExample)
EP (1) EP2958930A1 (enExample)
JP (1) JP6186012B2 (enExample)
KR (1) KR20150121712A (enExample)
CN (1) CN105102468A (enExample)
AR (1) AR094876A1 (enExample)
AU (1) AU2014218754B2 (enExample)
BR (1) BR112015019590A2 (enExample)
CA (1) CA2902513A1 (enExample)
EA (1) EA027861B1 (enExample)
IL (1) IL240739A0 (enExample)
MX (1) MX2015010354A (enExample)
SG (1) SG11201506445PA (enExample)
TW (1) TW201444862A (enExample)
WO (1) WO2014130810A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
KR20170135970A (ko) * 2015-04-14 2017-12-08 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙화 억제제를 생산하는 방법
CA3003721C (en) 2015-11-02 2024-02-06 Blueprint Medicines Corporation Inhibitors of ret to treat cancer
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018044838A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
CN106749486A (zh) * 2016-11-30 2017-05-31 沈阳化工大学 一种以乙二胺为连接臂的齐墩果酸衍生物及其应用
KR20200083969A (ko) 2017-09-14 2020-07-09 피닉스 바이오테크놀러지 인코포레이티드. 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물
RU2020113341A (ru) 2017-09-14 2021-10-15 Феникс Байотекнолоджи, Инк. Способ и композиция для лечения вирусной инфекции
CA3096043A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
CA3129743A1 (en) 2019-02-11 2020-08-20 Hetero Labs Limited Novel triterpene derivatives as hiv inhibitors
CN111440151A (zh) * 2020-03-25 2020-07-24 魏威 制备抗肿瘤药普拉赛替尼的方法
CN111362923A (zh) * 2020-03-25 2020-07-03 魏威 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法
JP7153083B2 (ja) 2020-03-31 2022-10-13 フェニックス・バイオテクノロジー・インコーポレイテッド コロナウイルス感染を治療するための方法および組成物
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
JP2023527412A (ja) 2020-05-29 2023-06-28 ブループリント メディシンズ コーポレイション プラルセチニブの固体形態

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
MXPA06010592A (es) 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US20090105203A1 (en) 2006-10-16 2009-04-23 Myriad Genetics, Incorporated Compounds for treating viral infections
WO2009100532A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. NOVEL 17ß LUPANE DERIVATIVES
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
SI2576586T1 (sl) * 2010-06-04 2015-11-30 Bristol-Myers Squibb Company C-28 amidi derivatov modificirane c-3 betulinske kisline kot inhibitorji zorenja hiv
CA2801487C (en) 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
AU2012212509B2 (en) * 2011-01-31 2016-01-21 ViiV Healthcare UK (No.4) Limited C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity
EA023578B1 (ru) * 2011-01-31 2016-06-30 Бристол-Маерс Сквибб Компани C28-амины c3-модифицированных производных бетулиновой кислоты в качестве ингибиторов созревания вич
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity

Similar Documents

Publication Publication Date Title
JP2016509062A5 (enExample)
JP2016507558A5 (enExample)
JP2015510515A5 (enExample)
JP2014507422A5 (enExample)
JP2014503595A5 (enExample)
JP2013527242A5 (enExample)
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
MX388757B (es) Profármacos de éster alifático antivíricos de tenofovir.
JP2013527243A5 (enExample)
FI4219508T3 (fi) Substituoitu polysyklinen pyridonijohdannainen ja sen aihiolääke
HRP20151212T1 (hr) C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
JOP20190115A1 (ar) مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp)
JP2014526554A5 (enExample)
UY35263A (es) Compuestos terapéuticos
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
EA201891876A1 (ru) Тетрациклические пиридоновые соединения в качестве противовирусных средств
NZ721534A (en) Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
MX381187B (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
JP2013032389A5 (enExample)
MA38922A2 (fr) Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX373713B (es) Compuestos pirazolopirimidina.
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.